# US 2014/0154710 A1 · Glycoprotein cancer biomarker > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154710 A1 - Document ID: US20140154710A1 - Status: Published application - Kind: A1 - Application number: 14/088,208 - Filed: 2013-11-22 - Published: 2014-06-05 - Earliest claimed: 2007-12-12 - Assignees: University of Georgia Research Foundation, Inc. - Applicants: University of Georgia Research Foundation, Inc. - Inventors: James Michael Pierce; Karen L. Abbott - Web page: https://patentgrep.com/patent/US20140154710A1 ## CPC - G01N 33/57515: of the breast - G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites} - G01N 2400/02: involving antibodies to sugar part of glycoproteins - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics. ## Claims ### Claim 1 A method for evaluating the presence, absence, nature or extent of ovarian cancer or a precancerous condition of the ovary, the method comprising: providing a biological sample obtained from a subject, the biological sample comprising glycoproteins; contacting the biological sample with a glycan-binding molecule specific for a glycan, under conditions that permit binding of the glycan-binding molecule to a glycoprotein comprising said glycan; detecting binding of the glycan-binding molecule to the glycoprotein to determine the presence, absence or amount of a cancer-specific glycoform of the glycoprotein in the biological sample, wherein said cancer-specific glycoform comprises the glycan and is indicative of ovarian cancer or a precancerous condition of the ovary; wherein the plurality of glycoproteins are selected from the group consisting of periostin (POSTN), biglycan (BGN), heparan sulfate proteoglycan 2 (HSPG2), lactate dehydrogenase A (LDHA), thrombospondin 1 (THBS1) serine protease inhibitor H1 (SERPINH1), lysosomal-associated membrane glycoprotein 1 (LAMP1), lectin galactosidase soluble binding protein 3 (LGALS3BP), complement factor B (CFB), fibulin 5 (FBLN5), mucin 5b (MUC5b), and lactotransferrin (LTF); and wherein the presence, absence or amount of the cancer-specific glycoform is indicative of the presence, absence, nature or extent of ovarian cancer or a precancerous condition of the ovary. ### Claim 2 (depends on 1) The method of claim 1 wherein the glycan-binding molecule comprises a detectable label. ### Claim 3 (depends on 1) The method of claim 1 wherein the glycan-binding molecule is selected from the group consisting of a lectin, a glycospecific antibody, a glycospecific aptamer, a glycospecific peptide, and a glycospecific small molecule. ### Claim 4 (depends on 1) The method of claim 1 wherein the lectin comprises at least one lectin selected from the group consisting of erythroagglutinating phytohemagglutinin (E-PHA), Aleuria aurantia lectin (AAL) and Datura stramonium lectin (DSL). ### Claim 5 (depends on 1) The method of claim 1 wherein the glycan comprises an α(1,6)-fucose linked to core N-acetylglucosamine (core fucosylation). ### Claim 6 (depends on 1) The method of claim 1 wherein the glycan comprises a GlcNAc β(1,4) Man bisected N-linked glycan. ### Claim 7 (depends on 1) The method of claim 1 wherein the biological sample comprises a biological fluid. ### Claim 8 (depends on 1) The method of claim 1 wherein the biological sample comprises serum or plasma. ### Claim 9 (depends on 1) The method of claim 1 wherein the biological sample comprises tissue. ### Claim 10 (depends on 1) The method of claim 1 wherein the subject is a human. ### Claim 11 (depends on 1) The method of claim 1 wherein the glycan comprises a bisecting N-linked glycan. ### Claim 12 (depends on 1) The method of claim 1 wherein the glycan comprises core fucosylation. ### Claim 13 (depends on 1) The method of claim 1 wherein the glycan comprises a tri- or tetra-antennary complex N-linked glycan. ### Claim 14 (depends on 1) The method of claim 1 wherein the glycan comprises a β(1,4) branched glycan. ### Claim 15 A method for evaluating the presence, absence, nature or extent of ovarian cancer or a precancerous condition of the ovary, the method comprising: contacting a biological sample obtained from a subject, with a glycan-binding molecule specific for a glycan under conditions that permit binding of the glycan-binding molecule to a glycoprotein comprising said glycan; and detecting binding of the glycan-binding molecule to the glycoprotein to determine the presence of a cancer-specific glycoform of the glycoprotein in the biological sample, wherein the cancer-specific glycoform comprises the glycan and is indicative of the presence of cancer or a precancerous condition of the ovary; and wherein the glycoprotein is selected from the group consisting of periostin (POSTN), biglycan (BGN), heparan sulfate proteoglycan 2 (HSPG2), lactate dehydrogenase A (LDHA), thrombospondin 1 (THBS1) serine protease inhibitor H1 (SERPINH1), lysosomal-associated membrane glycoprotein 1 (LAMP1), lectin galactosidase soluble binding protein 3 (LGALS3BP), complement factor B (CFB), fibulin 5 (FBLN5), mucin 5b (MUC5b), and lactotransferrin (LTF). ### Claim 16 A diagnostic composition comprising a biomarker comprising a cancer-specific glycoform of periostin comprising a bisected N-linked glycan component or core fucosylation. ### Claim 17 A diagnostic composition comprising a biomarker comprising a isolated cancer-specific glycoform of thrombospondin 1 (THBS1) comprising core fucosylation. ### Claim 18 A diagnostic composition comprising a biomarker comprising a cancer-specific glycoform of lysosomal-associated membrane glycoprotein 1 (LAMP1) comprising core fucosylation or a tri- or tetra-antennary complex N-linked glycan.